Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 7/20 | 0.53 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767209 | 0.83 | MLNR (0.76) | MLNRPRKAA2RORCHRH3MGLL | |
| SCHEMBL2765303 | 0.80 | MLNR (0.76) | MLNRHRH3 | |
| SCHEMBL2765888 | 0.76 | MLNR (0.66) | MLNRHRH3MGLL | |
| SCHEMBL2765767 | 0.75 | MLNR (0.76) | MLNRHRH3PTGDR2CCR1 | |
| SCHEMBL2768519 | 0.75 | MLNR (0.76) | MLNRPRKAA2HRH3MGLLCCR1 | |
| SCHEMBL3561143 | 0.74 | MLNR (0.71) | MLNRPRKAA2RORCHRH3MGLL | |
| SCHEMBL2766253 | 0.74 | MGLL (0.43) | RORCMGLLPTGDR2KCNH2 | |
| SCHEMBL2767002 | 0.74 | MLNR (0.61) | MLNRPRKAA2CCR1 | |
| SCHEMBL2769238 | 0.73 | MLNR (0.75) | MLNRPRKAA2HRH3MGLLCCR1 | |
| SCHEMBL2767820 | 0.73 | MLNR (0.57) | MLNRHRH3MGLLCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041093-B1 | PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD (GB) | 2010-04-21 | — | — | EP | disclosed |
| EP-2041093-A1 | PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008000729-A1 | PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |